详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Letter to the Editor: New confounders emerging with new evidence regarding reduced HCC and improved survival

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. [2]Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. [3]Biomedical Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, China.

出处：

DOI：

ISSN：

关键词： Finite Nuc therapy Metformin Glucagon-like peptide-1 Confounder

摘要：

To the Editor: Finite Nuc therapy (FNT) or continued Nuc therapy (CNT), which is better to reduce HCC incidence and improve survival in patients with HBeAg-negative HBV-related liver cirrhosis (HBV-LC)? With great interest, we read the article[1] that compared FNT with CNT for HCC incidence/ survival profile by Jeng et al. The authors found that compared with continuous Nuc therapy, FNT could reduce HCC incidence and improve survival in HBeAg-negative HBV-LC.[1] However, metformin and glucagonlike peptide-1 receptor agonists (GLP-1RAs), the new confounders discovered with new compelling evidence,[2-5] should be taken into account in the propensity score matching and multivariate cox regression analyses to avoid confounding bias.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 1 区

医学

小类 | 1 区胃肠肝病学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区胃肠肝病学

第一作者：

第一作者机构： [1]Department of Paediatric Genetics, Endocrinology and Metabolism, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Metformin targets multiple signaling pathways in cancer [2]Metformin as a booster of cancer immunotherapy [3]14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma [4]The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis. [5]14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma [6]Metformin attenuates chronic lung allograft dysfunction: evidence in rat models [7]Metformin Sensitizes Leukemia Cells to Vincristine via Activation of AMP-activated Protein Kinase [8]Metformin overcomes chemoresistance by regulating stemness via KLF4 in oral squamous cell carcinoma [9]Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release [10]The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct.